Tvardi to Present at Healthcare Conference
News related to:Tvardi Therapeutics, Inc · 2 min read
HOUSTON, Oct. 14, 2026 /CourierPR/ -- Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will present at Chardan’s 10th Annual Healthcare Conference in New York City on Tuesday, October 20, 2026, at 1:30 PM.
The presentation will provide an update on the company’s pipeline and progress in developing its lead product candidates, TTI-109 and TTI-101. TTI-109 is in a Phase 1 healthy volunteer study, while TTI-101 is in a Phase 1b/2 clinical trial for hepatocellular carcinoma. The company plans to initiate clinical trials of TTI-109 in gastrointestinal (GI) diseases pending IND clearance and the availability of additional funding.
The company’s focus on STAT3, a central mediator across critical signaling pathways that drive immune dysregulation, inflammation, and proliferation, positions it at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Tvardi’s lead product candidate, TTI-109, is currently in a Phase 1 healthy volunteer study, and the company plans to initiate clinical trials of TTI-109 in gastrointestinal diseases pending IND clearance and the availability of additional funding.
In addition, Tvardi is conducting a Phase 1b/2 clinical trial of TTI-101 in hepatocellular carcinoma (NCT05440708). The Phase 1b/2 trial is designed to evaluate the safety and efficacy of TTI-101 in patients with advanced hepatocellular carcinoma. The company’s research into STAT3 and its role in inflammatory and proliferative diseases is expected to provide valuable insights into the treatment of these conditions.
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases. The company’s pipeline includes TTI-109, which is in a Phase 1 healthy volunteer study, and TTI-101, which is in a Phase 1b/2 clinical trial for hepatocellular carcinoma. The company’s research into STAT3 and its role in inflammatory and proliferative diseases is expected to provide valuable insights into the treatment of these conditions.
The company’s presentation at Chardan’s 10th Annual Healthcare Conference in New York City on October 20, 2026, at 1:30 PM, will provide an update on the progress of its clinical trials and the potential for its lead product candidates to treat inflammatory and proliferative diseases. The presentation will also highlight the company’s focus on STAT3 as a central mediator across critical signaling pathways that drive immune dysregulation, inflammation, and proliferation.